BioNan-X

BioNan-X is a pre-clinical stage biotechnology company focused on developing a proprietary synthetic nanoparticle platform for targeted drug delivery. Spun out from the University of Nottingham, the company's technology mimics the properties of natural exosomes to enhance the delivery of therapeutic payloads across challenging biological barriers, including the blood-brain barrier. Their lead research programs are directed toward oncology, with a specific emphasis on treating glioblastoma and other central nervous system malignancies. By utilizing exosome-like synthetic vesicles, BioNan-X aims to improve the efficacy and safety profiles of both existing and novel therapeutic agents. The platform is designed to be versatile, capable of carrying small molecules, proteins, and nucleic acids.